论文部分内容阅读
[目的]探讨多西他赛联合泼尼松3周方案治疗激素难治性晚期前列腺癌的临床效果及毒副反应。[方法]12例激素难治性晚期前列腺癌患者接受治疗方案:多西他赛75mg/m2,d1,静脉滴注;泼尼松5mg,2次/d,d1～21口服;每21d为1个周期。[结果]12例中66.6%(8/12)PSA下降≥50%,为治疗有效;16.7%(2/12)PSA下降<50%,为病情稳定;16.7%(2/12)PSA持续上升,为治疗无效。有骨痛的9例患者中,55.6%(5/9)骨痛缓解,平均缓解期为14.3个月。多发性颅内转移灶最大转移瘤直径由化疗前的2.5cm缩小至0.5cm,肝脏转移瘤由原来的5.0cm缩小至2.4cm,肺转移灶最大转移瘤直径由化疗前的3.2cm缩小至1.0cm,气促缓解,膀胱转移患者化疗后血尿完全消失。全组最主要的毒副反应为骨髓抑制和呕吐。[结论]多西他赛联合泼尼松3周方案治疗激素难治性前列腺癌有一定疗效,毒性可耐受。
[Objective] To investigate the clinical effect and toxicity of docetaxel combined with prednisone for 3 weeks in the treatment of hormone-refractory advanced prostate cancer. [Method] Twelve patients with hormone-refractory advanced prostate cancer underwent treatment regimen: docetaxel 75 mg / m2, d1, intravenous drip; prednisone 5 mg twice daily, d1-21 oral; A cycle. [Results] The PSA of 66.6% (8/12) decreased by 50% or more in 12 cases, which was effective for treatment. The PSA decreased by <50% in 16.7% (2/12) , Invalid for treatment. Of the 9 patients with bone pain, 55.6% (5/9) had pain relief and the mean remission was 14.3 months. The diameter of maximal metastasis of multiple intracranial metastases was reduced from 2.5cm to 0.5cm before chemotherapy, the metastasis of liver was reduced from 5.0cm to 2.4cm, and the diameter of the largest metastatic tumor in lung metastases was reduced from 3.2cm before chemotherapy to 1.0 cm, relieve irritability, hematuria completely disappeared after chemotherapy in patients with bladder metastasis. The main group of toxic and side effects of bone marrow suppression and vomiting. [Conclusion] Docetaxel combined with prednisone for 3 weeks has some curative effect on hormone refractory prostate cancer and its toxicity is tolerable.